CHICAGO — They're not cures, but two novel drugs produced unprecedented gains in survival in separate studies of people with melanoma, the deadliest form of skin cancer, doctors reported Sunday.
In one study, an experimental drug showed so much benefit so quickly in people with advanced disease that those getting a comparison drug were allowed to switch after just a few months.
The drug, vemurafenib, targets a gene mutation found in about half of all melanomas. The drug is being developed by Genentech, part of Swiss-based Roche, and Plexxikon Inc., part of the Daiichi Sankyo Group of Japan.
The second study tested Bristol-Myers Squibb Co.' s Yervoy, a just-approved medicine for newly diagnosed melanoma patients, and found it nearly doubled the number who survived at least three years.
The new studies were presented Sunday at the American Society of Clinical Oncology's annual meeting in Chicago and published online by the New England Journal of Medicine.
"This is really an unprecedented time of celebration for our patients," said Lynn Schuchter of the University of Pennsylvania's Abramson Cancer Center. The new drugs are not by themselves cures, but "the future is going to be to build upon the success" by testing combinations of these newer drugs, she said.
Melanoma is on the rise. There were 68,000 new cases and 8,700 deaths from it in the United States last year, the American Cancer Society estimates.